Who
Kevin Charles Gorman
Director
Company insider
Files Form 4 as: Chief Executive Officer, Neurocrine Biosciences; Director, Xencor.
In numbers
- Trades disclosed
- 251
- Buys
- 1
- Sells
- 66
- Bought
- $1,013
- Sold
- $219.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 19 Jan 2006
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —14,343 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $1.2M7,839 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —14,343 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $1.2M7,839 at $156.22 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR Xencoroption or derivative · Biotechnology | SEC FORM 4 Code A | —20,604 at $0.00 | filing |
| 16 Jun 2026filed 8 Jul 2026 | XNCR XencorBiotechnology | SEC FORM 4 Code A | —10,302 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $93K7,527 at $12.31 | filing |
| 15 Jun 2026filed 17 Jun 2026 | XNCR XencorBiotechnology | SEC FORM 4 Sold | $93K7,527 at $12.31 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,248 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —5,248 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $8.9M205,088 at $43.24 | filing |
| 19 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $37.8M245,088 at $154.33 | filing |
| 19 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —205,088 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —205,088 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $8.9M205,088 at $43.24 | filing |
| 19 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $37.8M245,088 at $154.33 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —5,604 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $375K3,024 at $124.12 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Kevin Charles Gorman; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.